Breast cancer is a heterogeneous disease manifested as a range of different molecular subtypes of clinical relevance identified by gene expression analyses or biomarker expression [@R1],[@R2]. Breast tumors of the luminal subtypes (A or B) are the most common and characterized by expression of hormone receptors for estrogen (ERα) and/or progesterone (PgR), whereas 10-15% of women carry tumors of the basal-like subtype that do not express hormone receptors [@R3]. The prognosis and predictive characteristics of each breast cancer subtype are reflected by the adjuvant therapy options that are offered for that particular group of patients [@R4]--[@R6]. Patients carrying luminal tumors typically benefit from treatment with drugs impinging on ERα signaling, such as tamoxifen, fulvestrant or aromatase inhibitors [@R7]. In contrast, out of all breast carcinomas, the basal-like tumors have the highest recurrence rate, the shortest time to recurrence and worst overall survival rate due to a paucity of therapeutic targets [@R1],[@R3],[@R8],[@R9]. Thus, novel treatment approaches for basal-like breast cancer patients are urgently required.

The breast cancer subtypes are defined by characteristics of the malignant cells. However, this tumor cell-centric view does not take into account the context in which cancer cells subsist. As the cancerous lesion progresses, the surrounding microenvironment co-evolves into an activated state through continuous paracrine communication, thus creating a dynamic signaling circuitry that promotes malignant initiation and progression [@R10]. Hence, from a therapeutic perspective, tumors must be regarded as multi-cellular organs. Cancer-associated fibroblasts (CAFs) are a major constituent cell type of the tumor stroma and are known to support many different aspects of tumor growth and progression by secretion of growth stimulatory, angiogenic, immune-modulatory, and pro-invasive factors [@R11],[@R12]. However, the potential of CAFs as therapeutic targets or prognostic/predictive biomarkers is still debated, illustrating the possibility that CAFs represent a heterogenous group of cells with diverse and opposing functions [@R13],[@R14]. Indeed, a recent study defined histological subtypes also of the fibroblastic stroma of breast carcinomas, based on morphological criteria and marker expression [@R15].

We have previously demonstrated a role for signaling by platelet-derived growth factors (PDGFs) in the recruitment and functionality of CAFs in solid tumors, such as melanoma and cervical carcinoma [@R16],[@R17]. While CAFs have been reported to express both PDGF receptors, *i.e.* PDGFRα and PDGFRβ, specificity arises from the preference of receptor activation by the five different PDGF ligand isoforms (PDGF-AA, -AB, -BB, -CC, -DD). The *in vivo* specificity of one of the novel PDGF isoforms, PDGF-CC, remains undetermined, although *in vitro* studies suggest that PDGF-CC may activate PDGFRα homodimers, as well as PDGFRα/β heterodimers[@R18],[@R19]. Herein, we delineate a previously unappreciated role for paracrine signaling by PDGF-CC in CAFs as a determinant of breast cancer prognosis and treatment response through specification of the molecular subtype of the tumor. In translational efforts, we found that PDGF-CC expression in the malignant epithelium of breast cancer was associated with a hormone receptor-negative state; this finding was replicated in independent cohorts of patients. Genetic or pharmacological targeting of PDGF-CC in experimental mouse models resulted in conversion of basal-like breast tumors into an ERα-positive state that conferred sensitivity to endocrine therapy in previously impervious tumors. Our work sheds light on previously unknown mechanisms that define breast cancer subtype and has significant therapeutic implications for patients with basal-like breast tumors.

Results {#S1}
=======

PDGF-CC is an independent prognostic factor for poor survival in breast cancer {#S2}
------------------------------------------------------------------------------

To investigate the expression pattern of PDGF-CC in human breast cancer, we performed immunostaining of a tissue microarray containing 890 tumor specimens, as well as normal breast tissues (The Zürich cohort [@R20]; for patient characteristics, see [Supplementary Table 1](#SD2){ref-type="supplementary-material"}). The expression of PDGF-CC in normal breast tissue was limited to myoepithelial/basal cells and endothelial cells in capillaries, whereas PDGF-CC expression was not detected in luminal epithelial cells ([Fig. 1a-b](#F1){ref-type="fig"}). In breast tumors, PDGF-CC was expressed by malignant cells, intra-tumoral capillaries and stromal fibroblasts ([Fig. 1c](#F1){ref-type="fig"}). Notably, PDGF-CC immunoreactivity was most conspicuous at the border between stromal tissue and malignant epithelium ([Fig. 1d](#F1){ref-type="fig"}). Next, we evaluated the staining intensity for PDGF-CC independently for the epithelial and stromal compartment (for scoring schemes, see [Supplementary Fig. 1a-b](#SD2){ref-type="supplementary-material"}) and correlated these findings to clinico-pathological parameters. Both stromal and malignant epithelial expression of PDGF-CC were positively correlated to the grade and proliferative index of the tumor, but not to the stage or lymph node status ([Supplementary Table 2](#SD2){ref-type="supplementary-material"}). Stromal immunoreactivity for PDGF-CC was not associated with patient outcome in Kaplan-Meier analysis, or identified as a risk factor for poor survival in univariate Cox regression analysis ([Supplementary Fig. 1c and Table 1](#SD2){ref-type="supplementary-material"}). By contrast, moderate to high expression of PDGF-CC in malignant cells (score of 1+ to 3+) was found to be a statistically significant prognostic factor for poor survival ([Fig. 1e](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). Importantly, multivariable Cox regression analysis adjusting for established clinical risk factors, such as age at diagnosis, stage, grade, lymph node status, hormone receptor expression, among others, demonstrated that epithelial expression of PDGF-CC served as an independent prognostic factor for poor survival in breast cancer ([Table 1](#T1){ref-type="table"}).

Our findings were corroborated in a second breast cancer cohort of 550 patients (The Lund cohort [@R21],[@R22]; for patient characteristics see [Supplementary Table 3](#SD2){ref-type="supplementary-material"}), in which high epithelial expression of PDGF-CC was correlated to grade and associated with poor survival ([Supplementary Table 4 and Supplementary Fig. 1d](#SD2){ref-type="supplementary-material"}). Both receptors of the PDGF family, *i.e.* PDGFRα and PDGFRβ, were prominently and uniformly expressed by stromal fibroblasts in tumors from the Lund cohort ([Supplementary Fig. 1e-f](#SD2){ref-type="supplementary-material"}; PDGFRα and PDGFRβ expressed by CAFs in 482/489 (98.6%) and 480/480 (100%) of evaluable tumors, respectively). These findings indicate that malignant cells engage in a functional paracrine communication with mesenchymal cells of the tumor microenvironment through PDGF signaling.

PDGF-CC is functionally important for the growth of experimental breast cancer *in vivo* {#S3}
----------------------------------------------------------------------------------------

To investigate the functional aspects of PDGF-CC expression in the context of mammary gland tumorigenesis, we generated a genetically engineered mouse model of breast cancer based on the widely studied and relevant MMTV-PyMT mouse [@R23],[@R24] intercrossed with mice carrying an insertion of a *lacZ* cassette that inactivates the gene for PDGF-CC [@R25] (*Pdgfc*^-/-^ mice). Visualization of PDGF-CC, PDGFRα and PDGFRβ expression in tumors of MMTV-PyMT mice demonstrated faithful recapitulation of the expression pattern in human breast cancers, thus establishing the existence of a paracrine PDGF circuitry between malignant cells and stromal fibroblasts ([Supplementary Fig. 2a-d](#SD2){ref-type="supplementary-material"}). Strikingly, genetic deficiency for *Pdgfc* severely impacted on the growth of mammary tumors in MMTV-PyMT mice ([Fig. 1f](#F1){ref-type="fig"}). Control mice presented with tumors of an average size of 220 ± 47 mm^3^, whereas deficiency for a single or both copies of *Pdgfc* significantly reduced the average tumor size to 96 ± 41 mm^3^ and 87 ± 71 mm^3^, respectively ([Fig. 1f](#F1){ref-type="fig"}). Genetic deficiency for *Pdgfc* was also associated with a significantly longer tumor latency, as well as prolonged survival of the mice ([Supplementary Fig. 3a-b](#SD2){ref-type="supplementary-material"}). In line with the findings in human breast cancer, histological analyses revealed that tumors from *Pdgfc*^-/-^ mice were of lower grade compared to tumors from age-matched control animals ([Fig. 1g-i](#F1){ref-type="fig"}) and had significantly increased areas of necrosis ([Fig. 1g and j-k](#F1){ref-type="fig"}). We also observed a trend towards fewer pulmonary metastases in 14 weeks old tumor-bearing mice in the absence of PDGF-CC signaling ([Supplementary Fig. 3c](#SD2){ref-type="supplementary-material"}). However, this was most likely due to the delayed onset of disease, as a cohort of wt mice with grade-matched tumors to the Pdgfc-deficient cohort displayed a similar metastatic burden as the mice lacking *Pdgfc* ([Supplementary Fig. 3c](#SD2){ref-type="supplementary-material"}).

To ascertain that the delayed tumor development in *Pdgfc*-deficient mice was not due to developmental defects, we transplanted fragments of tumors from MMTV-PyMT; *Pdgfc*^+/+^ and MMTV-PyMT; *Pdgfc*^-/-^ mice orthotopically into the mammary fat pad of wt mice. Whereas all (21/21) transplanted wt tumor fragments established as growing tumors, only about half (11/21, χ^2^ test p=0.003) of the transplanted *Pdgfc*-deficient fragments gave rise to tumors. Consistent with our findings in the transgenic setting, transplanted *Pdgfc*-deficient tumors displayed a dramatically hampered growth, compared to *Pdgfc*-proficient tumors ([Fig. 1l](#F1){ref-type="fig"}). In addition, whereas two independently isolated cell lines from tumors in wt MMTV-PyMT mice (PeRo-Bas1 and PeRo-Bas2 cells) readily gave rise to exponentially growing tumors following orthotopic transplantation into the mammary fat pad of wt mice, cell lines from tumors in MMTV-PyMT; *Pdgfc*^-/-^ mice (PeRo-Lum1 cells and PeRo-Lum2 cells) failed to efficiently establish as palpable tumors ([Supplementary Fig. 3d-e](#SD2){ref-type="supplementary-material"}).

*Pdgfc* deficiency results in a blunted fibrotic and angiogenic response in the tumor microenvironment {#S4}
------------------------------------------------------------------------------------------------------

Histological analyses revealed considerable differences in the tumor architecture between MMTV-PyMT; *Pdgfc^+/+^* and MMTV-PyMT; *Pdgfc^-/-^* mice. Masson's tri-chrome staining of tumor sections demonstrated a severely reduced deposition of intra-tumoral collagen in the matrix of *Pdgfc*-deficient tumors, consistent with the notion that PDGF-CC signaling promotes the recruitment and/or activation of stromal fibroblasts in the breast tumor microenvironment ([Fig. 1m-n](#F1){ref-type="fig"}). In support of this notion, quantitative RT-PCR analysis showed reduced abundance of mRNA transcripts of prototypical markers for CAFs, such as α-smooth muscle actin (*Acta2)*, fibroblast-specific protein 1 (*S100a4)* and PDGFRα (*Pdgfra)* in *Pdgfc^-/-^* tumor samples ([Fig. 1o](#F1){ref-type="fig"}, Student's t-test p\<0.01 for each marker). Tumors from MMTV-PyMT; *Pdgfc*^-/-^ mice exhibited significantly increased levels of hypoxia, as evidenced by immunostaining for HIF-1α, the master transcriptional regulator of hypoxia ([Supplementary Fig. 4a-c](#SD2){ref-type="supplementary-material"}). Consistently, quantitative RT-PCR analysis revealed a 65% reduction in vascular endothelial growth factor-A expression levels in the absence of PDGF-CC ([Supplementary Fig. 4d](#SD2){ref-type="supplementary-material"}). Furthermore, in line with the increased abundance of necrotic area, these tumors were severely hemorrhagic ([Supplementary Fig. 4e](#SD2){ref-type="supplementary-material"}). Neutralization of PDGF-CC by administration of the inhibitory antibody 6B3 to tumor-bearing SCID mice delayed the growth and angiogenic response of orthotopic basal-like MDA-MB-231 tumors ([Supplementary Fig. 5a-c](#SD2){ref-type="supplementary-material"}). Taken together, genetic and pharmacological blockade of PDGF-CC corroborate a role for paracrine signaling in breast tumor growth, CAF recruitment and angiogenesis.

Expression of PDGF-CC in breast tumors is associated with a basal-like molecular subtype {#S5}
----------------------------------------------------------------------------------------

To elucidate the molecular signature of *Pdgfc*-deficiency, we performed transcriptional analysis of tumors derived from MMTV-PyMT; *Pdgfc*^+/+^ and MMTV-PyMT; *Pdgfc*^-/-^ mice using a quantitative RT-PCR array designed to analyze a targeted panel of genes instrumental in breast tumor development and progression. The most differentially regulated gene was found to be *Foxa1*, which was expressed on average 17.2-fold higher in whole tumor lysates from *Pdgfc*-deficient MMTV-PyMT mice compared to wt mice, and 6.5-fold higher in cell lines isolated from tumors lacking *Pdgfc* ([Fig. 2a](#F2){ref-type="fig"} and [Supplementary Fig. 6a](#SD2){ref-type="supplementary-material"}). The association between FoxA1 expression and loss of PDGF-CC was further corroborated at the protein level in whole tumor lysates of mammary carcinomas from MMTV-PyMT; *Pdgfc*^+/-^ mice and MMTV-PyMT; *Pdgfc*^-/-^ mice ([Supplementary Fig. 6b](#SD2){ref-type="supplementary-material"}).

Next, we set out to determine the functional implications of high expression of *Foxa1* in *Pdgfc*-deficient breast tumors. Analysis of transcriptional profiles of 1086 breast tumors collected within The Cancer Genome Atlas network [@R26] revealed that expression of *FOXA1* was highly correlated with a non-basal-like molecular subtype ([Supplementary Fig. 6c](#SD2){ref-type="supplementary-material"}), confirming previous studies [@R1],[@R27],[@R28]. In accordance with the association between *FOXA1* and luminal subtype breast cancer, tumors from *Pdgfc*-deficient MMTV-PyMT mice with high levels of FoxA1 protein also exhibited robust expression of ERα, as judged by western blot analysis ([Supplementary Fig. 6b](#SD2){ref-type="supplementary-material"}). Given the fact that *Foxa1* was found to be upregulated in experimental breast tumors in the absence of *Pdgfc*, we investigated the correlation between *FOXA1* and *PDGFC* in human breast cancer. Mining of transcriptional data from a panel of 51 breast tumor cell lines [@R29] demonstrated expression of *FOXA1* as a specific feature of cell lines of the luminal subtype, whereas basal-like cell lines did not express meaningful levels of *FOXA1*, as expected ([Fig. 2b](#F2){ref-type="fig"}). In contrast, high expression of *PDGFC* was predominantly observed in breast tumor cell lines of the basal-like subtype, but not in cells of luminal subtype origin ([Fig. 2c](#F2){ref-type="fig"}). Indeed, the expression of *PDGFC* and *FOXA1* exhibited a statistically significant inverse correlation in this panel of cell lines ([Fig. 2d](#F2){ref-type="fig"}). The enrichment for expression in basal-like breast tumor cell lines was exclusively observed for *PDGFC*, and not for other members of the PDGF family ([Fig. 2e](#F2){ref-type="fig"}). To investigate whether the absence of *PDGFC* was associated with a full luminal gene regulatory program, we analyzed the enrichment of binding sites for the luminal-defining transcription factors *ESR1*, *FOXA1*, and *GATA3*, as derived from public datasets of ChIP-seq analysis of luminal MCF7 and T47D cells [@R30], in the most differentially expressed genes in E~2~-stimulated *Pdgfc*-deficient PeRo-Lum1 cells compared to *Pdgfc*-proficient PeRo-Bas1 cells. While we were unable to demonstrate further induction of *Esr* target genes by E~2~ in PeRo-Lum1 cells, the basal expression level was superior in PeRo-Lum1 cells compared to PeRo-Bas1 cells, suggesting a constitutive activation of ERα signaling. In relation to 10^5^ randomly permuted gene lists of 1000 genes, both the top 1000 overexpressed genes, and the top 1000 underexpressed genes, in the *Pdgfc*-deficient cells were significantly enriched for orthologous human genes with *ESR1*, *FOXA1*, and *GATA3* binding sites in both MCF7 and T47D cells ([Fig. 2f-k](#F2){ref-type="fig"} and [Supplementary Fig. 6d-g](#SD2){ref-type="supplementary-material"}), indicating activation of a global luminal gene regulatory program in the absence of *Pdgfc*. In further support of the existence of an activated ERα pathway in PeRo-Lum1 cells, Gene Set Enrichment Analysis (GSEA) demonstrated that treatment with tamoxifen resulted in enrichment of documented ERα target genes or genes with documented sensitivity to tamoxifen ([Supplementary Fig. 7](#SD2){ref-type="supplementary-material"}). Additionally, tamoxifen treatment of *Pdgfc*-deficient breast cancer cells induced a gene profile related to decreased cell cycle progression, demonstrating manifestation of functional ERα signaling in PeRo-Lum1 cells ([Supplementary Fig. 7](#SD2){ref-type="supplementary-material"}). Finally, we also submitted a list of genes ranked by their correlation to the expression of *PDGFC* in breast tumors included in The Cancer Genome Atlas to GSEA. Consistently, genes that were inversely related to *PDGFC* expression were part of datasets identifying ERα target genes, whereas genes that were positively correlated to *PDGFC* expression were part of datasets related to inhibition of ERα signaling ([Supplementary Fig. 8](#SD2){ref-type="supplementary-material"}). Jointly, our analyses utilizing a diverse set of approaches strongly point to an association between the absence of expression of *PDGFC* and a luminal phenotype characterized by functional ERα signaling.

Next, we further investigated the association of PDGF-CC expression with the molecular subtype of breast cancer by analysis of expression of basal-like and luminal markers in the Zürich cohort of human breast tumors by immunostaining ([Table 2](#T2){ref-type="table"} and [Supplementary Fig. 9](#SD2){ref-type="supplementary-material"}). Strikingly, PDGF-CC showed a highly significant correlation to the basal-like markers cytokeratin (CK) 5/6 and epidermal growth factor receptor (EGFR), while low expression of PDGF-CC denoted hormone receptor-positive tumors expressing FOXA1, ERα and PgR ([Table 2](#T2){ref-type="table"}). The inverse correlation between PDGF-CC and hormone receptors was further corroborated in the Lund cohort, in which the relationship was also established in synchronous lymph node metastases and asynchronous distant metastases ([Fig. 2l-m](#F2){ref-type="fig"} and [Supplementary Table 5](#SD2){ref-type="supplementary-material"}). In primary tumor epithelium, only 7.8% of the luminal A subgroup were positive for PDGF-CC, whereas 71.9% of triple negative tumors were positive ([Supplementary Table 6](#SD2){ref-type="supplementary-material"}). Taken together, we have revealed a close association between expression of PDGF-CC and hormone receptor-negative breast tumors in cohorts of human patients.

A paracrine signaling circuit in stromal fibroblasts established by PDGF-CC determines the molecular subtype of breast tumor cells {#S6}
----------------------------------------------------------------------------------------------------------------------------------

We then investigated the molecular mechanisms through which paracrine signaling by epithelium-derived PDGF-CC was associated with basal-like features of breast tumors. Conditioned medium from the immortalized breast CAF cell line CAF2 [@R31] significantly reduced the sensitivity of PeRo-Lum1 mammary carcinoma cells with luminal features isolated from a tumor in a MMTV-PyMT; *Pdgfc^-/-^* mouse to tamoxifen-induced growth arrest ([Fig. 3a](#F3){ref-type="fig"}). This finding suggested that secreted factors from stromal fibroblasts conferred resistance to endocrine therapy. Next, we stimulated CAF2 cells with PDGF-CC and performed global transcriptional analysis. A list of statistically significantly upregulated genes (fold change \>1.4) was generated and filtered for Gene Ontology terms "Extracellular space" and "Extracellular region". The resulting list of genes was used to generate hypotheses concerning which factors mediated the effect of PDGF-CC, and candidate secreted proteins that were highly induced by PDGF-CC were tested for their ability to regulate the sensitivity of luminal breast cancer cells to the action of tamoxifen. The most significant findings, stanniocalcin 1 (*Stc1*), hepatocyte growth factor (*Hgf*) and insulin growth factor binding protein 3 (*Igfbp3*) were validated by quantitative RT-PCR to ensure robust induction by PDGF-CC in CAF2 cells after 48h of stimulation ([Supplementary Fig. 10](#SD2){ref-type="supplementary-material"}). Strikingly, pre-treatment with a cocktail of the CAF-derived factors HGF, IGFBP3 and STC1 reduced the sensitivity of PeRo-Lum1 cells to tamoxifen-induced growth arrest ([Fig. 3b](#F3){ref-type="fig"}). We also assessed whether stimulation of PeRo-Lum1 cells with HGF, IGFBP3 and STC1 converted their ERα-positive phenotype into ERα-negative. Indeed, while each factor alone affected the expression of luminal markers *Esr1*, *Foxa1* and *Gata3* to some degree, the concerted action of HGF, IGFBP3 and STC1 substantially suppressed the luminal-like features of *Pdgfc*-deficient mammary carcinoma cells ([Fig. 3c-e](#F3){ref-type="fig"}). The expression of HGF, IGFBP3 and STC1 by CAFs populating the stroma of tumors from MMTV-PyMT; *Pdgfc*^+/+^ mice was further confirmed by immunostaining ([Fig. 3f-h](#F3){ref-type="fig"}). Reassuringly, in breast tumors from the TCGA cohort, gene expression of *PDGFC*, *HGF* and *IGFBP3* were all significantly, albeit modestly, correlated to each other and to *FOXC1*, a transcriptional regulator of the basal-like phenotype [@R32] ([Fig. 3i](#F3){ref-type="fig"}), suggesting commonality in their regulation also in human tumors. By contrast, and in line with our observations, the expression of *PDGFC*, *HGF* and *IGFBP3* were inversely correlated to the luminal markers *FOXA1*, *ESR1* and *GATA3* ([Fig. 3i](#F3){ref-type="fig"}). In support, a cohort of 43 triple-negative breast cancer specimens displayed a close correlation between the expression of HGF, IGFBP3 and STC1 in the tumor stroma ([Supplementary figure 11a-c and Supplementary table 7](#SD2){ref-type="supplementary-material"}). All three factors were also variably expressed by the tumor epithelium, but a lack of close correlation in expression indicates distinct mechanisms of gene regulation (Matteo Bocci, data not shown). Similarly, immunostaining and scoring of a representative selection of 58 human breast tumors included in the Tam2Y cohort[@R33] for epithelial PDGF-CC, stromal HGF, stromal IGFBP3 and stromal STC1 demonstrated their close correlation with each other and with a basal-like, ERα-negative phenotype ([Supplementary table 8](#SD2){ref-type="supplementary-material"}). In summary, paracrine signaling by PDGF-CC stimulates the expression of HGF, IGFBP3 and STC1 in breast CAFs from luminal tumors, leading to a malignant cell phenotype denoted by lack of ERα and other luminal markers, and a reduced sensitivity to tamoxifen.

Genetic or pharmacological targeting of PDGF-CC sensitizes ERα-negative breast tumors to hormone therapy {#S7}
--------------------------------------------------------------------------------------------------------

ERα expression, which confers sensitivity to endocrine therapy such as tamoxifen, is the most important distinguishing clinical feature of luminal subtype breast tumors. We therefore investigated whether targeting of PDGF-CC would convey sensitivity to endocrine therapy to previously impervious ERα-negative breast tumors *in vivo*. Wildtype FVB/N mice bearing orthotopically transplanted tumors from MMTV-PyMT; *Pdgfc^+/+^* or MMTV-PyMT; *Pdgfc*^-/-^ mice were treated daily with tamoxifen starting from the time at which tumors were readily palpable. As expected, due to the lack of ERα expression at this late stage of malignant development, the wt tumors of tamoxifen-treated MMTV-PyMT mice continued to grow at a similar rate as tumors from control-treated mice ([Fig. 4a](#F4){ref-type="fig"}). In sharp contrast to the progressive growth of all wt tumors, *Pdgfc*-deficient tumors were severely growth-retarded upon treatment with tamoxifen and 71% (5/7) of the mice exhibited a complete or partial response (defined as full regression or shrinkage of tumor volume by more than 30%, respectively), in agreement with their expression of ERα ([Fig. 4b](#F4){ref-type="fig"}). At the end of the trial, tumors from tamoxifen-treated mice devoid of paracrine PDGF-CC signaling had a reduced volume by an average of 17%, whereas control-treated mice presented with tumors that had grown by 624% since treatment initiation, evidently revealing functional sensitization of ERα-signaling within *Pdgfc*-deficient breast tumors ([Fig. 4b](#F4){ref-type="fig"}).

To conclusively demonstrate the utility of agents targeting PDGF-CC to sensitize breast tumors of the basal-like subtype to the action of tamoxifen, we implanted the triple-negative patient-derived xenografts (PDX) 12.58 and 14.32, as well as the basal-like breast cancer cell line MDA-MB-231 orthotopically into immunocompromised mice. Indeed, analysis revealed that 12.58 and MDA-MB-231 tumors that originally did not express meaningful levels of ERα, substantially upregulated expression of ERα upon treatment with 6B3 as judged by immunostaining, corroborating the role of paracrine signaling by PDGF-CC in establishing ERα negativity in basal-like subtype breast tumors ([Fig. 4c-f](#F4){ref-type="fig"} and [Supplementary Fig 12a-d](#SD2){ref-type="supplementary-material"}). The upregulation of ERα expression in 12.58 and MDA-MB-231 tumors following PDGF-CC blockade was not uniform, but rather occurred focally in differentiated nests of malignant cells ([Supplementary Fig. 12a-d](#SD2){ref-type="supplementary-material"}). Importantly, 6B3-treatment was sufficient in itself to push 3/8 (37.5%) of the basal-like PDX tumors above the 1% threshold of ERα positivity used clinically to mandate treatment with endocrine therapy [@R34]. As expected, treatment with tamoxifen together with a control antibody was unable to influence the growth of fully established 14.32 or MDA-MB-231 tumors ([Fig. 4g-h](#F4){ref-type="fig"}). By contrast, and in good agreement with the converted ERα-positive phenotype upon neutralization of PDGF-CC, combined administration of tamoxifen and 6B3 led to significant growth retardation of both 14.32 and MDA-MB-231 tumors ([Fig. 4i-j](#F4){ref-type="fig"}). The frequency of ERα-positive cancer cells diminished in MDA-MB-231 tumors following tamoxifen therapy in combination with the 6B3 antibody, demonstrating that the induction of ERα caused by neutralization of PDGF-CC indeed invoked sensitivity to the action of tamoxifen ([Fig. 4f](#F4){ref-type="fig"}). Similarly, pharmacological blockade of PDGF-CC also brought about a growth delay of MDA-MB-231 xenografts in face of treatment with the aromatase inhibitor letrozole ([Supplementary Fig. 12e-f](#SD2){ref-type="supplementary-material"}), suggesting that the strategy is widely applicable to sensitize basal-like tumors to endocrine therapies such as tamoxifen and letrozole with diverse mechanisms of action. Conversely, mice xenografted with ERα-expressing luminal MCF7 cells with ectopic expression of *Pdgfc* did not respond to tamoxifen therapy, in contrast to mice implanted with the parental clone ([Fig. 4k](#F4){ref-type="fig"}). Jointly, our studies thus establish functional sensitization of ERα-negative tumors to endocrine therapy as a consequence of conversion into an ERα-positive state through blockade of paracrine signaling by PDGF-CC.

Discussion {#S8}
==========

We have revealed a paracrine signaling network manifested in the basal-like breast tumor microenvironment, in which tumor epithelium-derived PDGF-CC orchestrates specification of an ERα-negative phenotype through activation of CAFs that are induced to secrete HGF, IGFBP3 and STC1 ([Fig. 4l](#F4){ref-type="fig"}). Blockade of PDGF-CC, either by genetic or pharmacological means, prompted sensitization of previously impervious breast tumors to the action of endocrine therapy by inducing the expression of ERα ([Fig. 4l](#F4){ref-type="fig"}). Our findings unexpectedly identify CAFs as functional regulators of the molecular subtype of breast cancer, and offer novel therapeutic opportunities for a patient group in need of improved treatment options.

The distinguishing features of luminal and basal-like breast cancer cells have been thought to signify different cells-of-origin in the normal mammary gland, *i.e.* luminal progenitor cells and breast epithelial stem cells, respectively [@R35]. However, recent studies describe a high degree of plasticity and heterogeneity in the definition of luminal or basal-like tumors. Interconversion of luminal or basal-like tumor cells has been demonstrated to occur efficiently *in vitro*, indicating a common progenitor cell origin [@R36]. Indeed, based on gene expression analysis and functional studies, luminal progenitor cells have been proposed as a common source of luminal and basal-like breast carcinomas [@R37]--[@R40]. Moreover, a phenotypic switch from basal-like to luminal breast cancer can be achieved by introduction of the genes for ERα, FOXA1 or GATA3, whereas a transition from a basal-like state into a luminal state can result from epigenetic reprogramming [@R41]--[@R43]. Interestingly, cell cultures that were isolated from tumors in *Pdgfc*-deficient mice exhibited constitutive ERα signaling and a luminal phenotype, while retaining sensitivity to tamoxifen. Such tools may hold important clues as to the nature of the epigenetic programming of the molecular subtype of breast cancer. In line with our work, a recent study demonstrated development of tumors with differential ERα expression in lesions grafted from the same luminal PDX, but at different anatomical sites, *i.e.* the mammary fat pad or the milk ducts, suggesting profound microenvironmental regulation [@R44]. Rather than searching for new drugs targeting (epi)genetic alterations in basal-like breast tumors, pharmacological strategies for the induction of a switch from hormone receptor-negative breast cancer into a luminal subtype would offer established and effective treatment options for a large patient group in need of improved therapy. As such, our studies demonstrating that luminal/basal-like specification is under control of the tumor microenvironment through regulation of FOXA1, ERα and GATA3, afford novel targeting opportunities by interfering with paracrine signaling between malignant cells and CAFs.

Recent studies have suggested that PDGFRα expression may be a feature of malignant cells exhibiting stem cell properties and/or have undergone epithelial-to-mesenchymal transition in breast cancer [@R45],[@R46]. However, we have previously shown that malignant cell expression of PDGFRα is not a universal feature of human mammary carcinomas in the Lund cohort, as expression of PDGFRα in overt cancer cells was only found in 20% of cases [@R47]. In contrast, virtually all breast tumors in the same cohort harbored CAFs with expression of PDGFRα and PDGFRβ, strongly indicating that the paracrine mode of signaling by PDGF-CC, and not autocrine signaling, is the most prominent route of signal transduction in human breast cancers. Stimulation of breast CAFs with PDGF-CC induced the expression of HGF, IGFBP3 and STC1. Previous conditional PDGFRα gene targeting studies have demonstrated a reduced expression of HGF and collagen by fibroblasts, lending support to our findings [@R48]. Expression of the receptor for HGF, MET, has also been associated with basal-like breast cancer, in agreement with our study [@R49]--[@R52]. Intriguingly, constitutive activation of MET signaling drives commitment of luminal progenitor cells to a basal-like cell fate [@R53]. In the case of IGFBP3, the association with hormone receptor-negative breast cancers and poor survival is already well established, although a causal relationship has not been reported previously [@R54].

Mesenchymal cells are highly plastic entities. Normal fibroblasts are described to counteract tumorigenesis by repressing cancer initiation [@R14],[@R55],[@R56]. However, co-evolution of the malignant epithelium and its underlying stroma instigates activation of CAFs into a phenotype endorsing most, if not all, hallmarks of cancer progression [@R11],[@R57]. Abundant evidence thus supports the utility of CAFs as drug targets by virtue of their tumor-promoting abilities. Indeed, a recent study identified a subset of CD146-negative CAFs that confer resistance to endocrine therapy in luminal breast cancer[@R58]. However, investigations of pancreatic adenocarcinoma, a cancer type harboring severe desmoplasia, caution against indiscriminate blockade of CAF recruitment and/or activation [@R59],[@R60]. By the use of inhibitors of hedgehog signaling, or by eradication of α-SMA-expressing CAFs, genetically engineered pancreatic adenocarcinomas were allowed to thrive in an unrestricted manner. Given the diverse functions described, it is thus likely that CAFs represent a heterogenous population harboring both growth-promoting and -inhibitory subsets. Nevertheless, despite sometimes aggravating tumorigenesis, blockade of CAF recruitment sensitized pancreatic tumors to anti-angiogenic therapy or immune checkpoint inhibitors [@R59],[@R60]. Similarly, we found that blockade of signaling by PDGF-CC held utility as a combination partner to endocrine therapy in experimental mammary carcinomas. Therapeutic targeting of CAFs may thus best be exploited in joint treatment regimens with drugs impinging on multiple cell types and signaling pathways that collectively sustain malignant growth.

The work presented here identifies a hitherto unappreciated role of the tumor microenvironment in the specification of the molecular subtype of breast cancer and distinguishes PDGFRα-expressing CAFs as a promising pharmacological target to achieve manifestation of ERα in mammary carcinomas. As such, our discovery of neutralization of PDGF-CC as an efficacious combination partner to endocrine therapy justifies clinical evaluation for the treatment of patients suffering from basal-like breast cancer.

Online Methods {#S9}
==============

Further information on experimental design and reagents can be found in the accompanying Life Sciences [Reporting Summary](#SD1){ref-type="supplementary-material"}

Patient cohorts {#S10}
---------------

The Zürich cohort includes tissues from 890 patients with primary invasive breast cancer, diagnosed at the Institute of Surgical Pathology, UniversitätsSpital Zürich, between 1965 and 2004 (median July 1999). All patients enrolled voluntarily under Institutional Review Board-approved protocols and sample donors gave written informed consent. The ethics committee SPUK surgical-anesthetic-pathology at university hospital of Zürich, Switzerland, approved this study with reference number: *StV 12-2005*. For all these patients follow-up data from the cantonal cancer registry were available; patients without follow-up information were not considered [@R61]. Additionally, 69 normal tissues were analyzed. The Lund cohort includes patients with primary breast cancer from a prospective, observational trial evaluating various prognostic markers (local ethical review board reference numbers LU692-99 and LU247-01); clinical-pathological and follow-up data have previously been reported [@R62],[@R63]. Informed consent was obtained from all patients. Breast cancer-specific mortality was used as the endpoint and data on survival was retrieved from the Swedish Register of Causes of Death (Central Statistics Office). All events until December 2010 were recorded. The specimens from the Tam2Y cohort consists mainly of postmenopausal patients with stage II breast carcinoma from the South Swedish Health Care Region between 1985 and 1994[@R64]. For the current study, a representative subset of 58 tumors from the cohort was analyzed. The cohort of human triple-negative breast cancers was obtained commercially (Abcam, ab214756) and consisted of 43 evaluable specimens.

Immunohistochemistry on human tumor tissue arrays {#S11}
-------------------------------------------------

To assess PDGF-CC expression in clinical samples, the monoclonal PDGF-CC antibody 6B3 (2 μg/ml) was used on an automated Ventana platform (protocol CC1m for pre-treatment, UView HRP detection system). Specific immuno-reactivity was fully blocked by an excess of active PDGF-CC. The basal cell marker cytokeratin CK5/6 (1:25, clone cocktail D5/16B4, Dako), HER2 (1:50, clone 10A7 Novocastra, UK), EGFR (pre-diluted, clone 3C6 Ventana) and Ki-67 (1:20, clone Mib-1 Dako) were processed in parallel. Additionally, immunostaining was performed for HGF (1:100, Abcam ab83760), IGFBP3 (1:100, Santa Cruz Biotechnology sc-9028), and STC1 (1:100, Santa Cruz Biotechnology sc-30183).

Animals {#S12}
-------

All animal experiments were approved by the Ethical Committee for Animal Experimentation (Stockholm Norra djurförsöksetiska nämnd, application N96/11, and Lund/Malmö djurförsöksetiska nämnd, application M142/13) or by the Austin hospital Animal Ethics Committee. Experimentation were conducted in compliance with the Australian Code for the care and use of animals for scientific purposes. FVB/N-Tg(MMTV-PyVT)^634Mul/J^ transgenic mice have been described previously [@R65] and were purchased from The Jackson Laboratory. The presence of the MMTV-PyMT transgene and the generation of heterozygous and homozygous knock-out *Pdgfc* [@R66] offspring were verified by genotyping. DNA was prepared from either ear or tail biopsies according to a common tissue lysis, nucleic acid extraction and purification protocol.

MMTV-PyMT primer pair (5' to 3'): GGAAGCAAGTACTTC ACAAGGG and GGAAAGTCACTAGGAGCAGGG.

*Pdgfc* wild-type pair (5' to 3'): AGCTGACAT TTGATGAGAGAT and AGTAGGTGAAATAAGAGGTGAACA.

*Pdgfc* mutant pair (5' to 3'): CTC ATGTTCTCGTGACTCTGA and TAGCTAGTCGATACCGTCGA.

Mice deficient for *Pdgfc* were originally in the C57Bl/6 background and backcrossed to the FVB/N background for 10 generations before analysis was commenced. Female mice were used throughout the studies. In all cases, wt littermate mice were used as controls to genetically engineered mice.

Animal experiments {#S13}
------------------

For transgenic MMTV-PyMT mice, tumor size of each of the 10 mammary glands were measured at 12 weeks of age using a caliper. Tumor volume was calculated as length × width^2^ × π/6. The endpoint for survival analysis was taken as the time at which the combined tumor burden surpassed the ethical guidelines in our permit.

For transplantation experiments, 3 weeks old FVB/N female mice were anesthetized and maintained under Isoflurane during the surgical procedure. A 4 mm incision under the nipple of the right abdominal mammary gland created a pocket where a 2x2 mm tumor piece (pieces kept on ice derived from either MMTV-PyMT; *Pdgfc*^+/+^ mice or MMTV-PyMT; *Pdgfc*^-/-^ mice) was inserted. Suturing was performed with 6-0 Ethilon polyamide filament (Ethicon). Pain-killer and anti-inflammatory Rimadyl (5 mg/kg body weight; Orion Pharma Animal Health) was injected i.p. at the end of the surgical procedure and for the following two days. Tumor growth was monitored and measured in sedated mice twice per week with a caliper.

Mouse mammary cell lines derived from wt or *Pdgfc*-deficient MMTV-PyMT mice established in our laboratory were orthotopically injected into the 4^th^ inguinal mammary gland of wt FVB/N mice. Tumor growth was monitored and measured in sedated mice twice per week with a caliper.

For therapeutic studies, 2 × 10^6^ Human MDA-MB-231 cells were inoculated orthotopically in SCID mice. Mice had been randomly assigned before tumor inoculation to receive treatment with anti-PDGF-C (mouse monoclonal antibody clone 6B3) antibody or IgG2a isotype control antibody (Bio X Cell), which were delivered *via* i.p. injection twice a week (300 μg per week) starting from the day of tumor establishment. For therapeutic trials involving endocrine therapy, when a tumor was palpable (longest diameter \>3 mm), mice were alternately assigned into the treatment groups in which mice were treated with tamoxifen (1 mg/dose via oral gavage daily, Sigma), dissolved in a vehicle of ethanol and corn oil (Sigma) by heating to 55 °C, or with vehicle alone. All therapeutic administrations were open-label.

For all transplantation experiments, tumor growth was monitored and measured in sedated mice twice a week with a caliper.

Patient-derived xenografts {#S14}
--------------------------

A total of 8 mice (Nod Scid gamma, NSG) were implanted with 1-2 mm^3^ tumor pieces of patient-derived triple negative breast cancers with documented high expression of PDGF-CC (12.58, BRCA2 mutation, derived from liver metastasis, treatment resistant; 14.32, derived from primary tumor, treatment naïve). Two tumor pieces were implanted per mouse, in two mammary fat pads, one on each side of the mouse. Ten days after implantation, mice received anti-PDGF-CC therapy (50 mg/kg ch6B3, three times per week) or vehicle control (PBS). Tumors were harvested and fixed in 10% formalin. Four μm sections of the paraffin-embedded tumors were mounted onto SuperFrost® Plus slides (Menzel-Glaser, Braunschweig, Germany), deparaffinized and rehydrated prior to antigen retrieval for 36 min at 95°C in CC1 buffer (Ventana Medical Systems Inc, Tuscon, AZ, USA). Ready-to-use CONFIRM anti-estrogen receptor (ER) antibody, clone SP1 (Ventana Medical Systems Inc.) was applied to sections for 40 min at 36 °C. To allow visualization of the immunostaining, sections were incubated with the UltraView Universal DAB Detection Kit (Ventana Medical Systems Inc.) and counterstained with Mayer's haematoxylin. The staining was performed on board the Ventana BenchMark Ultra automated immunohistochemical staining instrument (Ventana Medical Systems Inc).

Mouse tissue preparation, histology and immunostaining {#S15}
------------------------------------------------------

To preserve tissues for downstream analysis, mice were heart-perfused with PBS followed by 4% paraformaldehyde. For paraffin-embedding, organs were post-fixed in 4% paraformaldehyde for 12 h in 4 °C. Paraffin-embedded sections were deparaffinized and re-hydrated followed by antigen retrieval in citrate buffer (pH 6; DAKO) in a pressure cooker (ERα) or in 95 °C water-bath for 20 minutes (STC1, IGFBP3 and HGF). Endogenous peroxidase activity was quenched with 3% H~2~O~2~ in methanol for 10 minutes at room temperature, followed by washes with 0.1% BSA in PBS.

ERα staining required subsequent steps in M.O.M. blocking (Mouse on Mouse basic kit, Vectorlabs), CAS-block (Life Technologies) and M.O.M. diluent. The primary antibody against estrogen receptor ERα (1:200, clone 1D5; DAKO) was incubated in M.O.M. diluent. CAS-block was used for the blocking and incubation of primary antibodies against STC1 (1:200, sc-30183, Santa Cruz Biotechnology), IGFBP3 (1:200, sc-9028 Santa Cruz Biotechnology) and HGF (1:200, ab83760 Abcam). Primary incubation was performed overnight at 4 °C in a humidified chamber. After washing, appropriate secondary biotinylated antibodies and the ABC peroxidase system were used (ABC Elite standard kit, Vector Laboratories) with DAB as substrate (Vector Laboratories).

For cryopreservation, primary tumor and lungs were kept in 30% sucrose at 4 °C overnight, followed by embedding in Optimal Cutting Temperature medium (HistoLab). Frozen sections were fixed in ice-cold acetone, followed by blocking using Serum Free Protein Block (DAKO) for \> 90 minutes at room temperature. Primary antibodies directed against PDGFRα (PE-conjugated, 1:200, 12-1401 eBioscience) and PDGFRβ (1:200, 3169S, Cell Signaling) were incubated overnight at 4 °C in a humidified chamber. Appropriate Alexa488- fluorochrome-conjugated secondary antibody (Life Technologies) was used and sections were finally mounted using 4´,6-diamidino-2-phenylindole (DAPI)-containing mounting media (Vector Laboratories).

Imaging was performed using an upright microscope (Eclipse E800; Nikon) equipped with Plan Fluor objectives (10×, 0.30 NA; 20×, 0.50 NA; 40×, 0.75 NA; Nikon) at room temperature in air. Images were acquired using a SPOT RTKE camera using the SPOT advanced software (Diagnostic Instruments, Inc.).

β-galactosidase staining {#S16}
------------------------

Fresh frozen sections were left to dry at RT for 15 minutes before washing in permeabilization solution (4mM MgCl~2~, 0.04% NP-40, 0.02% deoxycholic acid sodium salt in PBS) 2x30 minutes. Sections were further subjected to X-gal solution (5mM K3Fe(CN)6, 5mM K4Fe(CN)6, 1mg/ml 5-bromo-4-chloro-3-indole-6-D-galactosidase) and incubated over night at 37°C in a humidified chamber. After washing in permeabilization solution 3x30 minutes, sections were counterstained with Nuclear-Fast Red solution (Sigma), dehydrated and mounted in Pertex (Histolab).

Tumor grade assessment {#S17}
----------------------

Tumor tissue from MMTV-PyMT;*Pdgfc*^+/+^, MMTV-PyMT;*Pdgfc*^+/-^ and MMTV-PyMT;*Pdgfc*^-/-^ mice (n = 5 mice/genotype, 10 tissue sections per mouse) was classified into different degrees of progression by quantifying the area of transformed glands occupied by each stage. Progression follows from normal fat tissue to a "precancerous stage" characterized by premalignant hyperplasia and adenoma (with the retention of some normal ductal and acinar mammary gland morphology), to a more epithelial cell--dense "early carcinoma" with stromal invasion, and finally to an invasive, very dense, high--mitotic index "late-stage carcinoma". Tumors were evaluated for the proportion of mammary fat tissue, hyperplastic tissue, adenoma, early carcinoma and late carcinoma. PDGF-C specific necrosis was described by a pathologist and scored blindly in the samples.

Quantification of metastases {#S18}
----------------------------

The lungs of MMTV-PyMT were embedded in paraffin upon tissue fixation. The metastatic burden was assessed by serial sectioning of the entire lung. Following hematoxylin and eosin staining of every 25th section, the number of metastatic foci (\>8 cells in diameter) was determined in at least 15 tissue sections per lung.

Quantitative reverse-transcription PCR {#S19}
--------------------------------------

For RNA isolation and preparation, primary tumors were snap-frozen and stored at -80 °C; cell cultures were scraped in PBS with a rubber policeman and centrifuged into a pellet. RNA was isolated using RNAeasy MiniKit (Qiagen). cDNA was prepared using iScript cDNA Synthesis Kit (Bio Rad). KAPA SYBR FAST qPCR Kit Master Mix (KAPA Biosystems) was used for quantitative real-time PCR. The mRNA expression was normalized to the housekeeping gene L19. For *Foxa1*, *Esr1*, *Pdgfra*, *Fsp1*, and *Acta2*, QuantiTect Primer assays (Qiagen) were used.

L19 primer pair (5' to 3'): GGTGACCTGGATGAGAAGGA and TTCAGCTTGTGGATGTGCTC.

*Gata3* primer pair (5' to 3'): CAATGCCTGCGGACTCTACC and GGTGGTGGTCTCGACAGTTCG.

Quantitative reverse-transcription PCR array {#S20}
--------------------------------------------

RNA isolation and cDNA synthesis was prepared as described above. qPCR array analyzing 84 mammary cancer specific genes was run according to the manufacturer´s instruction (Mouse Breast cancer RT^2^ Profiler™ PCR array, Qiagen). In brief, cDNA was mixed with 2xRT^2^ SYBR Green ROX FAST Mastermix and diluted with RNase-free H~2~O and added to the RT^2^ Profiler PCR Array. The PCR was run for 40 cycles; 95**°**C for 15s and 60° for 30s. Five separate tumors from transplanted FVB/N wt mice from MMTV-PyMT; *Pdgfc^+/+^* and MMTV-PyMT; *Pdgfc^-/-^* respectively were run in the qPCR array.

Western blot {#S21}
------------

A piece of tumor was minced in liquid N~2~ before homogenization in lysis buffer (50mM Tris-HCl pH 7,4, 150mM NaCl, 5mM EDTA, 1% Triton-X 100, 1% SDS with the addition of Roche Complete protease inhibitor and PhosSTOP) using a Precellys 24 instrument (Bertin Technologies). After 30 minutes incubation at 4 °C, followed by centrifugation for 10 minutes at 16000×g, the supernatant was collected and further subjected to sonication using Vibra-cell™ (Sonics & Materials, Inc.). The lysate was spun down at 16000×g and the pellet discarded. Protein concentration was determined using Pierce BCA Protein Assay Kit and measurement of the absorption at 562nm on a spectrophotometer. The protein suspension was mixed with 5× NuPAGE^**®**^ LDS Sample Buffer and NuPAGE^**®**^ Sample Reducing Agent (Life Technologies), denaturated at 96 °C for 10 minutes and separated by SDS-PAGE on a NuPAGE^**®**^ 4-12% polyacrylamide gel (Life Technologies). The proteins were transferred to a nitrocellulose filter using a dry blotting system (iBlot^**®**^2, Life Technologies). The membrane was blocked 1 hour with 5% BSA in TBST (0.1% Tween-20 in TBS) and incubated o at 4°C with primary antibody (FoxA1, 1:200, sc-6553 Santa Cruz Biotechnology Inc; ERα, 1:200, sc-542 Santa Cruz Biotechnology Inc; β-actin 1:5000, ab-8227 Abcam) in 5% BSA in TBST. After washing, secondary antibody was applied in 5% BSA in TBST and incubated for 1 hour at RT. The membrane was washed and developed with Amersham ECL™ Prime Western Blotting Detection Reagent (GE Healthcare Life Sciences). Luminescence signal was measured using FluorChem**®** Q imaging system (Alpha Innotech).

Cell culture {#S22}
------------

All cells were tested and found to be negative for mycoplasma infection routinely. PeRo-Bas1 cells and PeRo-Lum1 cells were derived from tumors in 12 weeks old MMTV-PyMT; *Pdgfc*^+/+^ mouse and MMTV-PyMT; *Pdgfc*^-/-^ mouse, respectively. Human MDA-MB-231 and MCF7 cells were obtained freshly from the American Tissue Type Collection. CAF2 is an immortalized cell line of human fibroblasts conditioned by tumor cells *in vivo* in mice[@R67]. All cells were maintained in culture in DMEM Glutamax (Invitrogen), supplemented with 1% Penicillin/Streptomycin and 10% fetal bovine serum.

Gene expression analyses of human breast tumors and cell lines {#S23}
--------------------------------------------------------------

RNA-seq data from 1086 breast tumors included in The Cancer Genome Atlas project were analyzed for gene expression and correlation to molecular subtype (<http://cancergenome.nih.gov/>, downloaded January 30^th^ 2015). Using R (3.1.1), the data were log2 transformed and breast cancer subtypes were classified using the PAM50 centroids [@R68] after centering the data around the median. For analysis of gene expression in breast cancer cell lines, data for 51 breast cancer cell lines was obtained from [@R69]. Probe-level data were merged on Entrez Gene IDs, centered, log2 transformed, and plotted using MedCalc version 11 (MedCalc Software, Belgium). For transcriptional analysis of genes induced by the stimulation of PDGF-CC in CAFs, starved CAF2 cells were induced for 48h with 100 ng/ml of PDGF-CC. Next, RNA was extracted as detailed above and samples with RIN\>9 were subjected to cDNA library preparation and RNA-seq. The data is available for download from the NCBI Geo database with accession\# GSE108835.

In vitro cell culture assays {#S24}
----------------------------

Candidate proteins for mediating the effect of PDGF-CC on the molecular subtype of breast cancer cells were selected from a list of genes predicted to encode secreted proteins (Gene Ontology terms: Extracellular space and Extracellular region) and found to be upregulated in CAF2 cells following stimulation with PDGF-CC (see above).

3 × 10^6^ PR-Lum1 cells were seeded in culture medium. After 24 hours, the cells were starved for 24 hours in DMEM Glutamax (Invitrogen), supplemented with 1% bovine serum albumin (BSA; Sigma Aldrich). The cells were next stimulated with rhSTC1 (400 ng/mL; BioVendor), rmHGF (30 ng/mL;), rmIGFBP3 (250 ng/mL; R&D), or combinations of these factors in starvation medium for 48 hours. The cell line CAF2 was used to produce CAF-conditioned medium by incubation for 48 hours in starvation medium. For 4-OH-tamoxifen treatment, 15000 cells were seeded in 96-well plates. After 24 hours incubation in growth medium, followed by 24 hours starvation, the cells were stimulated either with CAF-conditioned medium or recombinant factors, as described before. The cells were treated with increasing concentration of 4-OH-tamoxifen (0-5 μM; Sigma Aldrich) in the respective stimulation medium at day 4 and 6 post-seeding. The cell proliferation reagent WST-1 (Roche) was used for the viability assay at day 7.

Genomic analysis of breast cancer cell lines {#S25}
--------------------------------------------

PeRo-Bas1 and PeRo-Lum1 cells were seeded in normal DMEM growth media for 8 h (\#10-013-CVR, Corning supplemented with 10% FBS and 1XPEST) and subsequently starved for 24h in serum-free DMEM (\#10-014-CVR, Corning, supplemented with 1% Bovine Serum Albumin (Sigma-Aldrich) and 1XPEST). Cells were treated in starvation media using 5 µM estradiol (E2758, Sigma-Aldrich) and/or 5 µM 4-OH-tamoxifen (Sigma-Aldrich) for 48 hours before RNA isolation (RNeasy® Mini Kit, \#74106, Qiagen). EtOH was used as vehicle control and treatment medium was replenished every 24 hours. Samples prepared in quintuplicate biological repeats were checked for quality using a 2100 Bioanalyzer instrument (Agilent) (RIN range 9.6-10), used as templates to prepare libraries (TruSeq, Illumina), and subjected to RNA sequencing using a NextSeq instrument (Illumina). Raw sequencing data was de-multiplexed and merged into two fastq files (read 1 and read 2) for each sample using Picard tools ExtractIlluminaBarcodes and lluminaBasecallsToFastq (<https://broadinstitute.github.io/picard/>). Kallisto (v0.43.0)[@R70] was used for abundance estimation and differential expression analysis was performed with Sleuth (v0.29.0)[@R71]. Kallisto was run with parameters \--bootstrap-samples 100, \--bias, \--rf-stranded and the transcript target was the Gencode release M15 protein-coding transcript sequences. The resulting lists of the top 1000 differentially upregulated and 1000 downregulated genes in *Pdgfc*-deficient PeRo-Lum1 cells compared to *Pdgfc*-proficient PeRo-Bas1 cells were used to investigate the enrichment of regulated genes with *ESR1*, *FOXA1* and *GATA3* DNA binding sites, as determined by publicly available datasets from ChIP-seq analysis. ChIP-Seq datasets were obtained through the CistromeDB portal[@R72] and included E2-treated MCF-7 cells[@R73]: ESR1, FOXA1, and GATA3 (GSM589237, GSM659787, and GSM720422, respectively) and E2-treated T47D cells[@R73]: ESR1 and FOXA1 (GSM589239, and GSM659795, respectively). ChIP-Seq peaks were assigned to GRCh38 Ensembl gene transcripts (gencode_basic=TRUE, biotype=protein coding and miRNAs) and scored using the ClosestGene method[@R74]. The ClosestGene method assigns a ChIP-seq peak to the closest transcription start site, and scores the peak based on the empirical cumulative distribution of peaks around the transcription start site. Transcript scores were summed on the gene level and used to examine the enrichment of binding in the top up and down-regulated genes observed in the experiment. From the human ChIP-seq dataset we extracted 15 140 genes with homology between human and mouse using BiomaRt (filtering on ortholog_one2one, and homolog_orthology_confidence=1). The ChIP-Seq enrichment test was then confined to the intersection of genes with human/mouse homology and the 13 000 genes with detectable expression in the experiment (n=11 300). The summed score and number of genes with ChIP-Seq peaks of the top 1000 differentially expressed genes was compared to 10^5^ randomly sampled genelists. The sampled genelists were drawn from the pool of 11 300 genes to provide a relevant background. The number of bound genes and sum of scores in each re-sampled gene list was recorded and then ranked (the gene list with the highest score= rank 1) together with the results for the query lists. The rank of the query gene list divided by the total number of re-sample instances was then used as a p value for the probability to acquire the level of enrichment by chance.

For the analysis of gene expression in cell cultures following estradiol or tamoxifen treatment, we ranked all genes according to the Wald test statistic for differential expression. The Pearson\'s r correlation test was used to rank the genes that correlate to PDGFC within The Cancer Genome Atlas (TCGA) Breast carcinoma dataset (BRCA). GSEA was performed using the GseaPreranked tool in GSEA v3.0[@R75],[@R76] with 1000 random sample permutations, and utilizing the Molecular Signatures Database (MSigDB) hallmark (h.all.v6.1) and curated (c2.all.v6.1) gene sets. The GSEA statistics (Normalized Enrichment Score (NES), nominal P value and FDR q value) are presented in the figures.

Statistical analyses {#S26}
--------------------

All values depicted represent mean ± standard error of the mean. Statistical calculations were performed using IBM SPSS Statistics (version 22.0, IBM, Armonk, NY, USA) or GraphPad Prism 7 software. Statistical tests were applied as indicated in the figure legends in a two-sided, unpaired fashion with p\<0.05 considered significant. The variance was similar between experimental groups in each experiment, unless otherwise stated. *In vivo* experiments included cohorts of the size indicated in each figure legend, but at least 6 mice per group. Sample size was chosen by an estimate of the number of animals needed to detect a 20% difference in the primary endpoint of tumor growth rate, based on the experience of the authors. No animals entering the experimental/intervention phase were excluded from analysis. *In vitro* analyses were repeated 3-6 times to ensure reproducible conclusions, the exact number of repetitions is stated in each figure legend.

Data availability {#S27}
-----------------

Data from the transcriptional analysis of CAF2 cells stimulated with PDGF-CC is available through the NCBI GEO database with accession number GSE108835.
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![Epithelial expression of PDGF-CC is associated with poor outcome in human breast carcinoma.\
**a-d,** Immunostaining of normal breast tissue (a-b) or breast carcinoma (c-d) for PDGF-CC. Appropriate validation on \>10 independent samples was performed to ensure reproducible staining pattern on human tissue. Dotted line represents the epithelium-stroma boundary and arrows identify tumor cells with particularly high expression of PDGF-CC on the invasive border. Scale bar, 40 µm. **e,** Kaplan-Meier analysis of breast cancer-specific survival dichotomized according to absence (negative, n=438 samples) or presence (positive, defined as a score of 1+ to 3+, n=452 samples) of PDGF-CC in tumor cells (for scoring scheme, see [Supplementary Fig. 1a](#SD2){ref-type="supplementary-material"}) of breast carcinomas from the Zürich cohort. \*\* p=0.002, log-rank test **f,** Average volume (with SEM) of tumors from 14 weeks old MMTV-PyMT mice (n=10 animals in each group). \*\*\* p=0.0001, two-sided, unpaired, equal variance Student's t-test**. g,** Grading of tumors from 14 weeks old MMTV-PyMT mice (n=5 animals in each group). \* Distribution of *Pdgfc*^-/-^ vs *Pdgfc*^+/-^ p=0.036, χ^2^ test. \*\*\* Distribution of *Pdgfc*^-/-^ vs *Pdgfc*^+/+^ p=3\*10^-11^ and distribution of *Pdgfc*^+/-^ vs *Pdgfc*^+/+^ p=0.00052, χ^2^ test. **h-k,** Hematoxylin and eosin staining of tumors from MMTV-PyMT mice at 14 weeks of age. Scale bar, 500 µm. **l,** Average volume (with SEM) of tumors derived from MMTV-PyMT mice transplanted into the mammary fat pad of wt mice (n=21 animals in each group, composed of n=7 animals each from 3 independent experiments). \*\*\* p=6\*10^-6^, two-sided, unpaired, equal variance Student's t-test. **m-n,** Masson's tri-chrome staining of tissue sections from tumors from 14 weeks old MMTV-PyMT mice. Representative pictures from the analysis of n=10 animals from each group are shown. Scale bar, 500 µm. **o,** Quantitative real-time PCR analysis of the average expression (with SEM) of markers for cancer-associated fibroblasts in tumor lysates of tumors from 14 weeks old MMTV-PyMT mice (n=3 animals in each group, analysis performed independently 3 times). \*\* *Pdgfra*, p=0.007; *S100a4*, p=0.003; *Acta2*, p=0.009 two-sided, unpaired, equal variance Student's t-test.](emss-75725-f001){#F1}

![Expression of PDGF-CC in breast carcinomas is associated with the basal-like molecular subtype and hormone receptor negativity.\
**a,** Quantitative RT-PCR analysis of the luminal subtype marker *Foxa1* in tumors from 14 weeks old MMTV-PyMT mice (n=5 animals in each group, analysis performed independently 3 times). \*\*\* p\<0.001, two-sided, unpaired, equal variance Student's t-test. **b-c,** Expression of *FOXA1* (b) and *PDGFC* (c) in a panel of 51 breast cancer cell lines [@R29] divided according to basal-like or luminal-like molecular subtype. **d,** Correlation between expression of *FOXA1* and *PDGFC* in a panel of 51 breast cancer cell lines divided according to basal-like or luminal-like molecular subtype. Correlation coefficient and p-value from Pearson correlation analysis of n=26 basal cell lines and n=25 luminal cell lines. **e,** Expression of all PDGF family members in n=26 basal cell lines and n=25 luminal cell lines . Box represents the interquartile range, line represents the average expression and whiskers depict range of expression with statistical outliers indicated (\>2 standard deviations from the mean). \*\*\* p=1\*10^-6^, two-sided, unpaired Welch's unequal variances t-test. **f-k,** Enrichment of luminal-defining transcription factors *ESR1*, *FOXA1*, and *GATA3* binding sites, as derived from public datasets of ChIP-seq analysis in MCF7 cells, in the 1000 most up/down-regulated genes in *Pdgfc*-deficient PeRo-Lum1 cells compared to *Pdgfc*-proficient PeRo-Bas1 cells. Red, query signature; blue, n=10^5^ randomly sampled gene lists of equal size to the query signature; green, average of the randomly sampled gene lists. The rank of the query gene list divided by the total number of re-sample instances was then used as a p-value for the probability to acquire the level of enrichment by chance. **l-n,** Correlation between expression of ERα and PDGF-CC in primary breast carcinomas (l, n=470 independent samples, \*\*\* p=2.1\*10^-14^ independent samples, two-sided Jonckheere-Terpstra test for ordered alternatives), synchronous lymph nodes (m, n=132 independent samples, \*\*\* p=1.5\*10^-8^ independent samples, two-sided Jonckheere-Terpstra test for ordered alternatives) or asynchronous distant replapses (n, n=29 independent samples, \*\* p=0.0015 independent samples, two-sided Jonckheere-Terpstra test for ordered alternatives) included in the Lund cohort. Box represents the interquartile range, line represents the median expression and whiskers depict 1.5x the height of the box. Circles and stars represent statistical outliers that fall outside of the whiskers and extreme outliers that fall outside of 3x the height of the box, respectively.](emss-75725-f002){#F2}

![CAF-derived factors induced by PDGF-CC reduce the sensitivity of breast tumor cells to endocrine therapy.\
**a,** Viability of PeRo-Lum1 luminal breast cancer cells derived from MMTV-PyMT; *Pdgfc^-/-^* mice in the presence of increasing concentrations of 4-OH-tamoxifen in medium conditioned by tumor cells (TC) or CAFs (the average (with SEM) of n=6 independent experiments is shown). \*\* p\<0.01, \*\*\* p\<0.001, (p-values for control *vs* STC1+HGF+IGFBP3 for each tamoxifen concentration (1-5 µM=0.0001, 0.00001, 0.00001, 0.00001, 0.005, respectively), two-way ANOVA with p-values from Bonferroni post-hoc test. **b,** Viability of PeRo-Lum1 cells in the presence of increasing concentrations of 4-OH-tamoxifen in medium conditioned by nothing or STC1, HGF and IGFBP3 (the average (with SEM) of n=6 independent experiments is shown). \*\* p\<0.01, \*\*\* p\<0.001 (p-values for control *vs* STC1+HGF+IGFBP3 for each tamoxifen concentration (1-5 µM=0.003, 0.0003, 0.00008, 0.0002, 0.005, respectively), two-way ANOVA with p-values from Bonferroni post-hoc test. **c-e,** Quantitative RT-PCR analysis of the average expression (with SEM) of *Foxa1* (c, n=3 independent experiments), *Esr1* (d, n=3 independent experiments) or *Gata3* (e, n=2 independent experiments) in PeRo-Lum1 cells in the presence of combinations of STC1, HGF and IGFBP3. *Foxa1* \* p=0.03, \*\* p=0.002, \*\*\* p=0.0003, one-way ANOVA with p-values from Bonferroni post-hoc test. *Esr1* \* p=0.01, \*\* p=0.005, \*\*\* p=0.001, one-way ANOVA with p-values from Bonferroni post-hoc test. *Gata3* \* p=0.02, \*\* p=0.007, \*\*\* p=0.001, one-way ANOVA with p-values from Bonferroni post-hoc test. **f-h,** Immunostaining of tissue sections from tumors from 14 weeks old MMTV-PyMT mice for STC1 (f), HGF (g) or IGFBP3 (h). Immunostaining was performed n=3 independent times and representative images from n=5 tumors are shown. Scale bar, 100 µm. **i,** Pearson's correlation analysis of factors denoting luminal-like (*FOXA1*, *ESR1*, *GATA3*) or basal-like (*FOXC1, PDGFC*) molecular subtype in luminal subtype breast carcinomas included in the TCGA cohort (n=1086 independent tumors included in analysis).](emss-75725-f003){#F3}

![Genetic or pharmacological targeting of PDGF-CC induces expression of ERα and sensitizes tumors to endocrine therapy.\
**a-b,** Treatment of wt mice transplanted orthotopically with tumors derived from 14 weeks old MMTV-PyMT; *Pdgfc*^+/+^ mice (a) or MMTV-PyMT; *Pdgfc*^-/-^ mice (b) with oil vehicle (*Pdgfc*^+/+^ n=7 animals, *Pdgfc*^-/-^ n=6 animals) or tamoxifen (*Pdgfc*^-+/+^ n=6 animals, *Pdgfc*^-/-^ n=7 animals). Average tumor volume (with SEM) depicted. \*\* p=0.002, two-sided, unpaired, equal variance Student's t-test. X-axis shows time after start of therapy. **c-d,** Immunostaining for ERα (brown) of tissue sections from the triple-negative patient-derived xenograft 12.58 from mice treated with control IgG or 6B3. Immunostaining performed n=3 independent times and representative images are shown. Scale bar, 40 µm. **e,** Quantification of the average ERα expression (with SEM) in patient-derived xenograft 12.58 from mice treated with control IgG or 6B3 (IgG, n=7 animals; 6B3, n=8 animals). \*\*\* p=7\*10^-7^, χ^2^ test. **f,** Quantification of the average number of ERα-expressing cells (with SEM) in MDA-MB-231 tumors from mice treated with control IgG or 6B3 in combination with oil vehicle (IgG, n=10 animals; 6B3, n=12 animals) or tamoxifen (IgG, n=12 animals; 6B3, n=12 animals). \*\* p=0.003, two-sided, unpaired, equal variance Student's t-test. **g,** Treatment of mice carrying orthotopically transplanted triple-negative patient-derived xenograft 14.32 with control IgG in combination with vehicle (n=10 animals) or tamoxifen (n=10 animals). Average tumor volume (with SEM) depicted. X-axis shows time after start of therapy. **h,** Treatment of mice carrying orthotopically transplanted MDA-MB-231 tumors with control IgG in combination with oil vehicle (n=10 animals) or tamoxifen (n=12 animals). Average tumor volume (with SEM) depicted. X-axis shows time after start of therapy. **i,** Treatment of mice carrying orthotopically transplanted triple-negative patient-derived xenograft 14.32 with the neutralizing PDGF-CC antibody 6B3 in combination with vehicle (n=10 animals) or tamoxifen (n=10 animals). Average tumor volume (with SEM) depicted. \* p=0.03, two-sided, unpaired, equal variance Student's t-test. X-axis shows time after start of therapy. **j,** Treatment of mice carrying orthotopically transplanted MDA-MB-231 tumors with the neutralizing PDGF-CC antibody 6B3 in combination with oil vehicle (n=12 animals) or tamoxifen (n=13 animals). Average tumor volume (with SEM) depicted. \* p=0.025, two-sided, unpaired, equal variance Student's t-test. X-axis shows time after start of therapy. **k**, Treatment of mice carrying orthotopically transplanted MCF7 tumors infected with lentivirus carrying empty vector or *Pdgfc* vector with oil vehicle (Vector, n=9 animals; *Pdgfc*, n=10 animals) or tamoxifen (Vector, n=10 animals, *Pdgfc*, n=8 animals). Average tumor volume (with SEM) depicted. \* Vector + Tamoxifen *vs Pdgfc* + Tamoxifen, p=0.029, two-sided, unpaired, equal variance, Student's t-test. X-axis shows time after start of therapy. **l,** Schematic diagram of the paracrine action of PDGF-CC in the breast tumor microenvironment. An active crosstalk between malignant cells and CAFs mediated through PDGF-CC results in specification of the molecular subtype and regulation of sensitivity to endocrine therapy.](emss-75725-f004){#F4}

###### 

Cox regression analysis of risk factors for breast cancer death. RR -- relative risk, CI -- confidence interval, NA -- not analyzed, pT -- Primary tumor stage, pN -- Number of lymph nodes involved, G -- Nottingham histological grade, CK5/6 -- cytokeratin 5/6.

  Zürich cohort                                                                                
  ---------------------------- ------------------------- ----------- ------------------------- -----------
                                                                                               
  *Age at diagnosis*                                                                           
      60 years \< *vs* \>=     1.542 (1.170-2.032)       0.002       1.437 (1.035-1.995)       0.03
                                                                                               
  *Menopausal status*                                                                          
      pre *vs* post            1.355 (0.965-1.902)       0.079       NA                        NA
                                                                                               
  *pT*                                                                                         
      1-4                      1.611 (1.421-1.825)       \<0.001     1.624 (1.378-1.913)       \<0.001
                                                                                               
  *pN*                                                                                         
      0-3                      1.681 (1.423-1.986)       \<0.001     1.415 (1.173-1.708)       \<0.001
                                                                                               
  *G*                                                                                          
      1-3                      1.669 (1.341-2.077)       \<0.001     1.410 (1.067-1.862)       0.016
                                                                                               
  *ERα*                                                                                        
      negative *vs* positive   0.494 (0.364-0.670)       \<0.001     1.211 (0.757-1.937)       0.424
                                                                                               
  *PgR*                                                                                        
      negative *vs* positive   0.511 (0.388-0.673)       \<0.001     0.603 (0.411-0.886)       0.01
                                                                                               
  *HER2*                                                                                       
      0-2+ *vs* 3+             1.941 (1.373-2.745)       \<0.001     1.577 (1.041-2.388)       0.031
                                                                                               
  *CK5/6*                                                                                      
      negative *vs* positive   1.496 (1.010-2.217)       0.045       1.457 (0.891-2.382)       0.133
                                                                                               
  ***PDGF-CC Epithelium***                                                                     
      **0 *vs* 1-3+**          **1.520 (1.156-1.998)**   **0.003**   **1.484 (1.035-2.127)**   **0.032**
                                                                                               
  *PDGF-CC Stroma*                                                                             
      1+ *vs* 2-3+             0.931 (0.708-1.225)       0.931       NA                        NA

###### 

Spearman's rank correlations of PDGF-CC expression and FoxA1 expression with biomarkers for molecular subtypes. Correlation coefficients in bold are statistically significant. NA -- not analyzed.

  Zürich cohort            FoxA1                       ERα          PgR          CK5/6        EGFR         
  ------------------------ --------------------------- ------------ ------------ ------------ ------------ -----------
                                                                                                           
  **PDGF-CC Epithelium**   *Correlation coefficient*   **-0.180**   **-0.485**   **-0.301**   **0.331**    **0.303**
  *P-value*                0.002                       0.0001       0.0001       0.0001       0.0002       
                           *N*                         288          856          854          860          854
                                                                                                           
  **FoxA1**                *Correlation coefficient*   1.000        **0.454**    **0.299**    **-0.246**   NA
  *P-value*                NA                          0.0001       0.0001       0.0001       NA           
                           *N*                         315          285          309          310          NA
